|Day Low/High||3.55 / 3.75|
|52 Wk Low/High||2.92 / 9.29|
Industry Leading µPharm Technology Platform Delivers Initial Development Work in Just Four Months for New Oncology Drug Development
Fast Growing, Sustainable Skin Care Brand Partners with Leading Prestige Specialty Beauty Retailer to Meet Growing Consumer Demand for Sustainable Skin Care Products
Amyris's Leading µPharm™ Platform Focused on Rapid Discovery of Novel Antibiotic Compound Target
Investors in Amyris, Inc. saw new options begin trading this week, for the June 2017 expiration.
Includes up to $30 Million Collaboration Investment, $100 Million in Annual Revenue and Participation in Industrial Fermentation Facilities in Asia
Industry Recognition of Neossance and Accelerated Customer Adoption Continues to Fuel Record Sales Growth
Expected to Expand Global Availability of Farnesene for Variety of Applications
Strongest Operational Execution to Date while Successfully Moving the Business Beyond Biofuels
ARG Joins Amyris and Cosan with Equity Investment and Market Access to Accelerate Revenue Growth of Novvi High Performance, Sustainably Sourced, Renewable Lubricant Products
But in a narrow field, finding suppliers may be an issue.
Two Year Committed Jet Fuel Supply Deal Demonstrating Continued Strong Farnesene Demand
Gen9 and Amyris today announced an agreement for the supply of multiple megabases of synthetic DNA content.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.